Navigation Links
ABR-Affinity BioReagents to Exhibit at the Society for Biomolecular Sciences in St. Louis, April 6 - 10, 2008
Date:4/2/2008

DENVER and GOLDEN, Colo., April 2, 2008 /PRNewswire/ -- ABR-Affinity BioReagents, a leading global antibody manufacturer, announced today that it will exhibit for the first time at the 14th Annual Conference and Exhibition of the Society for Biomolecular Sciences (SBS) in St. Louis, April 6 - 10, 2008.

"We are extremely pleased to support the advancement of the science of drug discovery by exhibiting at the SBS meeting, especially as it is a non-profit forum. This is our first in what I foresee as a multiple year commitment to supporting this cutting edge area of basic and applied pharmaceutical research," said Ken Wilczek, President of ABR. "It is truly a privilege to be involved with these top-level, dedicated institutions and talented individuals in the furtherance of innovative drug discovery research that could lead to potentially life-saving therapies," continued Mr. Wilczek. ABR-Affinity BioReagents' high quality portfolio of monoclonal and polyclonal antibodies, recombinant proteins, siRNA and custom antibody and peptide production services are already in use by every major research institution, government agency, university, and pharmaceutical company in the world today.

"Feedback from leading researchers in the areas of cancer biology and disease research, especially arthritis and inflammation, is invaluable to us in determining strategic direction. The international character of this audience will enable ABR to collaborate on a meaningful level with the most influential scientists in the world," noted Mr. Wilczek. ABR-Affinity BioReagents will be located at booth #220.

About ABR-Affinity BioReagents

Founded in 1989 with world headquarters in Golden, Colorado, ABR-Affinity BioReagents is a world leader in the manufacture and distribution of monoclonal and polyclonal antibodies, kits, recombinant proteins, siRNA, and custom antibody production services, known as Antibody on Demand(R).

With more than 35,000 antibodies focused in 43 research areas, ABR offers a unique value proposition in the life science industry -- research antibodies that are 100% quality guaranteed or your money back -- with no questions asked.

Utilizing a distribution network encompassing over 55 nations, ABR products are readily available in every research market on the globe. Products are available directly from ABR in the United States, as well as through an exclusive distribution partnership with Fisher Scientific, a division of Thermo Fisher Scientific.

For additional information about ABR-Affinity BioReagents, contact Leslie Martin with ABR media relations at 1-800-527-4535.


'/>"/>
SOURCE ABR-Affinity BioReagents
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ABR-Affinity BioReagents Finalizes Agreement for Distribution of Osenses Antibodies in the U.S., Canada and Europe
2. ABR-Affinity BioReagents to Exhibit at ASCB in Washington D.C., December 1 - 5, 2007
3. ABR-Affinity BioReagents Announces Agreements for U.S. Distribution of Research Antibodies
4. Corgenix to Exhibit AspirinWorks(R) Test at ACC 2008 Meeting in Chicago
5. Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago
6. Biotechnology Leader to Exhibit at Upcoming Trade Show
7. BioInformatics, LLC Studies Trade Show Exhibition Strategies in the Life Science Market
8. West Michigan Science & Technology Initiative Seeks Exhibitors for Annual Life Science Showcase
9. Maryland Science Center Unveils Anatomical Exhibition, Body Worlds 2, on Saturday, February 2
10. Imaging Diagnostic Systems Exhibits at Major Middle East Health Conference
11. Kiwa Bio-Tech Products Group Holds a Fertilizer Products Exhibition in Hebei
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Feb. 12, 2016  PTC Therapeutics, Inc. ... annual STRIVE (Strategies to Realize Innovation, Vision and ... (DMD). STRIVE provides funds to patient advocacy organizations ... make meaningful contributions to the rare disease community ... of future patient advocates. Mary ...
(Date:2/11/2016)... NBIX ) today announced its financial results for the quarter ... --> For the fourth quarter of 2015, the ... per share, compared to a net loss of $19.4 million, or ... the year ended December 31, 2015, the Company reported a net ... to a net loss of $60.5 million, or $0.81 loss per ...
(Date:2/11/2016)... , Feb. 11, 2016  Bioethics International, a not-for-profit organization ... researched, developed, marketed and made accessible to patients around the ... had named the publication of the Good Pharma ... publication is also featured as one of BMJ Open ... last year that are most frequently read. Ed ...
(Date:2/11/2016)... (PRWEB) , ... February 11, ... ... business-to-business publication dedicated to delivering cutting-edge information focused on the development and ... Sciences to become a premier sponsor of the 2016 BioProcess International Awards ...
Breaking Biology Technology:
(Date:1/18/2016)... JOSE, Calif. , Jan. 18, 2016 /PRNewswire/ ... security software that simplifies the use and access ... technology and go-to-market partnership with American Cyber.  ... Cyber brings extensive experience leading transformational C4ISR and ... implementing and integrating the latest proven technology solutions," ...
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
(Date:1/11/2016)... , Jan. 11, 2016 Synaptics Incorporated ... interface solutions, today announced that its ClearPad ® ... (TDDI) products won two separate categories in the 8 ... Innovator and Best Technology Breakthrough. The Synaptics ® ... a simplified supply chain, thinner devices, brighter displays and ...
Breaking Biology News(10 mins):